Ching-Leou Teng
Isis Pharmaceuticals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ching-Leou Teng.
Pharmaceutical Research | 2001
Weiqi Lin; Michel J. N. Cormier; Ahmad P. Samiee; Angie Griffin; Bonny Johnson; Ching-Leou Teng; Gregory E. Hardee; Peter E. Daddona
In recent years, antisense oligodeoxynucleotide (ODN) technology has emerged as one of the most promising functional genomic therapies. Several clinical trials have demonstrated its therapeutic value and low toxicity (1). To date, parenteral infusion has been the primary mode of ODN delivery. However, efforts to develop more convenient routes of administration are being explored. Transdermal iontophoresis increased ODNs across the skin; however, delivery of a therapeutically relevant dose was not achieved (2–5). The major barrier for transdermal delivery is the stratum corneum, the outermost “dead” layer of the skin. In human skin, the stratum corneum is 10–20 m thick, whereas in mice and rats it is significantly thinner. Removal of the stratum corneum by mechanical abrasion, tape stripping, or chemical treatment has been shown to significantly enhance permeation through the skin for a wide range of pharmaceuticals, including phosphorothioated (PS) ODNs (5–8). However, these approaches may be limited due to the lack of control and reproducibility, as well as the irritancy potential (9). Microprojection patch is a novel microfabrication technology for controlled transdermal drug delivery. The patch system incorporates a stainless steel or titanium microprojection array. When applied onto the skin manually or by an applicator, microprojections penetrate and create superficial pathways through the skin barrier layer to allow drug delivery. The array can be combined either with passive or iontophoretic delivery systems. In this study, we demonstrate that microprojection patch technology can facilitate the controlled transdermal ODN delivery. MATERIALS AND METHODS
Archive | 2005
Ching-Leou Teng; Phillip Dan Cook; Lloyd Tillman; Gregory E. Hardee; David J. Ecker; Muthiah Manoharan
Archive | 1998
Ching-Leou Teng; Greg Hardee
Journal of Pharmaceutical Sciences | 2004
Araz A. Raoof; Peter Chiu; Zeibun Ramtoola; Iain Cumming; Ching-Leou Teng; Susan P. Weinbach; Greg Hardee; Arthur A. Levin; Richard S. Geary
Archive | 2002
Ching-Leou Teng; Susan Weinbch; Lloyd Tillman; Richard S. Geary; Gregory E. Hardee
Journal of Pharmaceutical Sciences | 2001
S. Kevin Li; Abdel-Halim Ghanem; Ching-Leou Teng; Gregory E. Hardee; William I. Higuchi
Journal of Pharmaceutical Sciences | 2008
Keiko Tsutsumi; S. Kevin Li; Richard V. Hymas; Ching-Leou Teng; Lloyd Tillman; Gregory E. Hardee; William I. Higuchi; Norman F.H. Ho
Archive | 2003
Greg Hardee; Eric E. Swayze; Rahul Mehta; Ching-Leou Teng; Art Levin; C. Frank Bennett; Lloyd Tillman; Richard S. Geary
Archive | 2002
Richard S. Geary; Gregory E. Hardee; Ching-Leou Teng; Lloyd Tillman; Susan P. Weinbach
Archive | 1999
Phillip Dan Cook; David J. Ecker; Gregory E. Hardee; Muthiah Manoharan; Ching-Leou Teng; Lloyd Tillman